TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18553122

Group type: EXPERIMENTAL
Intervention: Post-operative rofecoxib
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Peri-operative rofecoxib
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 79
Study: 16087308

Group type: EXPERIMENTAL
Intervention: Zaleplon
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Estazolam (as internal standard)
Number of subjects: 18
Study: 14631882

Group type: EXPERIMENTAL
Intervention: Context structuring with 16.7% related words
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Context structuring with 33% related words
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 38
Study: 11800418

Group type: EXPERIMENTAL
Intervention: Low-dose atorvastatin (10 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atorvastatin (both doses)
Number of subjects: 50
Study: 9674803

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7980302

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) vaginal pessaries
Number of subjects: 206

Group type: COMPARATOR
Intervention: Amniotomy plus oxytocin infusion
Number of subjects: 206
Study: 2691943

Group type: EXPERIMENTAL
Intervention: Factor AF2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no Factor AF2)
Number of subjects: 0
Study: 4850376

Group type: EXPERIMENTAL
Intervention: 0.25 mg digoxin tablet (Lanoxin)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: digoxin solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: oral administration of digoxin (0.25 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: intravenous administration of digoxin (0.25 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: urinary excretion of digoxin
Number of subjects: 6
Study: 31498937

Group type: EXPERIMENTAL
Intervention: Osteo-cise: Strong Bones for Life multicomponent exercise program (n = 81)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (n = 81)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Osteo-cise (per protocol analysis with ≥66% exercise adherence)
Number of subjects: 162
Study: 31446994

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg Q3W) as first-line therapy
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 264
Study: 29940953

Group type: EXPERIMENTAL
Intervention: Self-managed continuous monitoring
Number of subjects: 225

Group type: COMPARATOR
Intervention: Supervision (control)
Number of subjects: 225
Study: 26580275

Group type: EXPERIMENTAL
Intervention: HFR-iso
Number of subjects: 47

Group type: COMPARATOR
Intervention: HFR
Number of subjects: 47
Study: 23733488

Group type: EXPERIMENTAL
Intervention: 200 mg saffron tablets for 7 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 400 mg saffron tablets for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 60
Study: 22258269

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS)
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Antiretroviral drugs
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS) with antiretroviral drugs
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS) without antiretroviral drugs
Number of subjects: 2369
Study: 19130041

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet rich in natural fibre and moderate to vigorous leisure time physical activity)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Increased fibre intake and moderate to vigorous leisure time physical activity
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Changes in carbohydrate or fat intake
Number of subjects: 406
Study: 17998028

Group type: EXPERIMENTAL
Intervention: 1 meal per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3 meals per day
Number of subjects: 0
Study: 15249438

Group type: EXPERIMENTAL
Intervention: APAPfl (AutoSet device)
Number of subjects: 30

Group type: COMPARATOR
Intervention: APAPfot (SOMNOsmart device)
Number of subjects: 30
Study: 11999177

Group type: EXPERIMENTAL
Intervention: Instruction group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 10202984

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation applied daily for 10 days
Number of subjects: 10
Study: 9282669

Group type: EXPERIMENTAL
Intervention: Time-of-flight MR angiography
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intra-arterial contrast angiography
Number of subjects: 20
Study: 2314405

Group type: EXPERIMENTAL
Intervention: Bovine surfactant (20-40 mg/kg in group 1, 40-50 mg/kg in group 2)
Number of subjects: 32
Study: 85109

Group type: EXPERIMENTAL
Intervention: Epidural injection of 2 mg morphine
Number of subjects: 10
Study: 31606361

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 0
Study: 30944885

Group type: EXPERIMENTAL
Intervention: Highlights version of the informed consent document (Common Rule)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full-length version of the informed consent document
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other revised versions of the informed consent document
Number of subjects: 0
Study: 27264211

Group type: EXPERIMENTAL
Intervention: Isometric exercise (30% maximal voluntary contraction for 3 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition (quiet rest)
Number of subjects: 20
Study: 26419418

Group type: EXPERIMENTAL
Intervention: 1:1 cognitive tutoring for eight weeks
Number of subjects: 0
Study: 25251736

Group type: EXPERIMENTAL
Intervention: Dynamic SpineCor brace
Number of subjects: 68

Group type: COMPARATOR
Intervention: Natural evolution (control)
Number of subjects: 68
Study: 20870753

Group type: EXPERIMENTAL
Intervention: Nebulized gentamicin, 80 mg, twice daily for 12 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Nebulized saline, 0.9% for 12 months
Number of subjects: 65
Study: 19378225

Group type: EXPERIMENTAL
Intervention: Triaxial accelerometer (RT3, Stayhealthy, Monrovia, CA) worn during waking hours over a 14-day period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Triaxial accelerometer (RT3, Stayhealthy, Monrovia, CA) worn during mid-day hours (10AM to 4PM)
Number of subjects: 22
Study: 17540969

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 569

Group type: COMPARATOR
Intervention: Men
Number of subjects: 569
Study: 15223674

Group type: EXPERIMENTAL
Intervention: Sodium valproate (400 mg four times per day)
Number of subjects: 22
Study: 11268865

Group type: EXPERIMENTAL
Intervention: Chorioamnion cultures positive for coagulase-negative staphylococci (CONS)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Chorioamnion cultures negative for coagulase-negative staphylococci (CONS)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Culture-proven CONS in the NICU
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Adjusted odds ratio for CONS in chorioamnion
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Adjusted odds ratio for CONS in NICU
Number of subjects: 108
Study: 9642893

Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard Treatment (STD)
Number of subjects: 106
Study: 9820995

Group type: EXPERIMENTAL
Intervention: Captopril treatment
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Aldosterone
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: 3-month plasma atrial natriuretic peptide and aldosterone
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Neurohormones (atrial natriuretic peptide, aldosterone, norepinephrine)
Number of subjects: 534
Study: 2071264

Group type: COMPARATOR
Intervention: 800 mg of garlic powder for four weeks
Number of subjects: 0
Study: 6868954

Group type: EXPERIMENTAL
Intervention: 6 g of myoinositol daily for 2 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31672712

Group type: EXPERIMENTAL
Intervention: Active tDCS and AE
Number of subjects: 148

Group type: COMPARATOR
Intervention: Sham tDCS and AE
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Active tDCS and non-aerobic exercise (nAE)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Sham tDCS and nAE
Number of subjects: 148
Study: 29718393

Group type: EXPERIMENTAL
Intervention: High HPV-18 antibodies (third quartile)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High HPV-18 antibodies (fourth quartile)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High HPV-16 antibodies
Number of subjects: 0
Study: 26814256

Group type: EXPERIMENTAL
Intervention: DETERx IN
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: DETERx PO
Number of subjects: 39

Group type: COMPARATOR
Intervention: OXY‐IR IN
Number of subjects: 39
Study: 24998104

Group type: EXPERIMENTAL
Intervention: Lignocaine with pethidine 30mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lignocaine with ketoprofen 100mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lignocaine alone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (Lignocaine)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 45
Study: 21244601

Group type: EXPERIMENTAL
Intervention: Concurrent subcutaneous interleukin‐2 (IL‐2), interferon‐α2b (IFN‐α) and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Number of subjects: 60
Study: 21275334

Group type: EXPERIMENTAL
Intervention: Music therapy CD creation intervention
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 11
Study: 19026877

Group type: EXPERIMENTAL
Intervention: 6% sodium hypochlorite with EDTA
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate with EDTA
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Aquatine Endodontic Cleanser with EDTA
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Morinda citrifolia juice with EDTA
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 6% sodium hypochlorite with MTAD
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate with MTAD
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Aquatine Endodontic Cleanser with MTAD
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Morinda citrifolia juice with MTAD
Number of subjects: 38
Study: 16192912

Group type: EXPERIMENTAL
Intervention: 2‐CdA + prednisone (P)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Chlorambucil (Chl) + prednisone (P)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Chl + P followed by 2‐CdA + P
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 2‐CdA + P followed by Chl + P
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 2‐CdA + P
Number of subjects: 229

Group type: COMPARATOR
Intervention: Chl + P
Number of subjects: 229
Study: 12538369

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin E emulsion (all‐rac‐alpha‐tocopherol), 270 mg each, four doses between 16 h before and 48 h after surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin E emulsion (all‐rac‐alpha‐tocopherol)
Number of subjects: 40
Study: 10802497

Group type: EXPERIMENTAL
Intervention: Hypoallergenic amino acid‐based infant formula (AAF)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Previously best tolerated formula
Number of subjects: 19
Study: 9074533

Group type: EXPERIMENTAL
Intervention: 201Tl for perfusion and 99mTc blood‐pool labeling
Number of subjects: 20
Study: 8403515

Group type: EXPERIMENTAL
Intervention: rIL-2
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: rIL-2 with IFN-alpha
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: rIL-2 or rIL-2 with IFN-alpha
Number of subjects: 52
Study: 3811803

Group type: EXPERIMENTAL
Intervention: Bupivacaine warmed to 37 degrees C (warm group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine stored at 4 degrees C (cold group)
Number of subjects: 40
Study: 31392990

Group type: EXPERIMENTAL
Intervention: Acupuncture plus standard care
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 124
Study: 29258076

Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin
Number of subjects: 0
Study: 27039697

Group type: EXPERIMENTAL
Intervention: Long rest breaks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short rest breaks
Number of subjects: 0
Study: 24077370

Group type: EXPERIMENTAL
Intervention: Strength training sessions (twice per week) + in-water training
Number of subjects: 27

Group type: COMPARATOR
Intervention: In-water training only
Number of subjects: 27
Study: 22309790

Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI) via external beam with IMRT, 16 daily fractions of 270 cGy to a total dose of 4320 cGy.
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: APBI treatment stratified by ASTRO risk groups.
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: APBI treatment
Number of subjects: 310
Study: 20808103

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17197818

Group type: EXPERIMENTAL
Intervention: Combination of amprenavir, lopinavir and ritonavir (400 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimized nucleoside reverse transcriptase inhibitors
Number of subjects: 0
Study: 15738535

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy (paclitaxel followed by fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Chemotherapy (paclitaxel followed by fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 42
Study: 12002924

Group type: EXPERIMENTAL
Intervention: Midazolam + Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo + Propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midazolam + Propofol (with supplemental propofol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo + Propofol (with supplemental propofol)
Number of subjects: 60
Study: 7956294

Group type: EXPERIMENTAL
Intervention: Humid‐Vent Filter
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bennett Cascade 2 Humidifier
Number of subjects: 11

Group type: COMPARATOR
Intervention: Pall Ultipor Filter
Number of subjects: 11
Study: 2445214

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 224

Group type: COMPARATOR
Intervention: Antilymphoblast azathioprine
Number of subjects: 224
Study: 29569715

Group type: EXPERIMENTAL
Intervention: HPV self-collection brush (RIATOL qPCR HPV genotyping test)
Number of subjects: 35354

Group type: EXPERIMENTAL
Intervention: Opt-in group (offered the opportunity to order an HPV self-sampling brush)
Number of subjects: 35354

Group type: EXPERIMENTAL
Intervention: Standard recall letter
Number of subjects: 35354

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 35354

Group type: EXPERIMENTAL
Intervention: Self-sampling strategy
Number of subjects: 35354

Group type: EXPERIMENTAL
Intervention: hrHPV positive testing
Number of subjects: 35354

Group type: EXPERIMENTAL
Intervention: Self-sampler DNA concentration
Number of subjects: 35354
Study: 28259855

Group type: EXPERIMENTAL
Intervention: Restrictive fluid regimen (≤3.0 L in the first 24 hours)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Liberal fluid regimen (≥5.4 L in the first 24 hours)
Number of subjects: 3000
Study: 26147373

Group type: EXPERIMENTAL
Intervention: Newly designed thermal gown
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard cotton cloth
Number of subjects: 100
Study: 23186785

Group type: EXPERIMENTAL
Intervention: NF135.C10
Number of subjects: 5

Group type: COMPARATOR
Intervention: NF54
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: NF135.C10 and NF54
Number of subjects: 5
Study: 21262888

Group type: EXPERIMENTAL
Intervention: Short sleep duration and irregular sleep schedules in obese children
Number of subjects: 308

Group type: COMPARATOR
Intervention: Regular sleep patterns and longer sleep duration
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: High variance in sleep duration
Number of subjects: 308

Group type: COMPARATOR
Intervention: Average sleep duration of 8 hours per night
Number of subjects: 308
Study: 19226541

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs) used for less than the study duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-ASA NSAIDs used for less than the study duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer duration of NSAID use
Number of subjects: 0
Study: 17044084

Group type: EXPERIMENTAL
Intervention: LD + ENT treatment
Number of subjects: 30
Study: 15569202

Group type: EXPERIMENTAL
Intervention: Alternative therapy use
Number of subjects: 290

Group type: COMPARATOR
Intervention: Radiotherapy treatment
Number of subjects: 290
Study: 11022070

Group type: EXPERIMENTAL
Intervention: 3 intra-articular injections of 40 mg triamcinolone acetonide
Number of subjects: 37

Group type: COMPARATOR
Intervention: 1 mL physiological saline solution (placebo)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Triamcinolone group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study: 9288302

Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery (FES)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Caldwell‐Luc (C‐L) operations
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both FES and C‐L operations
Number of subjects: 150
Study: 8143886

Group type: EXPERIMENTAL
Intervention: zolpidem, 10 mg for 2 weeks (nights 8-21)
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo (nights 8-21)
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo (nights 22-28)
Number of subjects: 21
Study: 3539672

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Multiple insulin injections (MI)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 45
Study: 29909698

Group type: EXPERIMENTAL
Intervention: 30 readings (awaken)
Number of subjects: 4277

Group type: EXPERIMENTAL
Intervention: 1 reading (awaken)
Number of subjects: 4277

Group type: EXPERIMENTAL
Intervention: 30 readings (asleep)
Number of subjects: 4277

Group type: EXPERIMENTAL
Intervention: 1 reading (asleep)
Number of subjects: 4277

Group type: EXPERIMENTAL
Intervention: 10/5 mm Hg increments in systolic/diastolic ABP (awaken)
Number of subjects: 4277

Group type: EXPERIMENTAL
Intervention: 10/5 mm Hg increments in systolic/diastolic ABP (asleep)
Number of subjects: 4277

Group type: EXPERIMENTAL
Intervention: ≥8/≥4 readings (awaken/asleep)
Number of subjects: 4277
Study: 28681550

Group type: EXPERIMENTAL
Intervention: AZL-M/CLD 40/12.5 mg/d (initial dose, could be uptitrated to 80/25 mg)
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: AZL-M/CLD 40/12.5 mg/d
Number of subjects: 837

Group type: COMPARATOR
Intervention: OLM/HCTZ 20/12.5 mg/d (initial dose, could be uptitrated to 40/25 mg or 20/25 mg)
Number of subjects: 837

Group type: COMPARATOR
Intervention: OLM/HCTZ 20/12.5 mg/d
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: AZL-M/CLD
Number of subjects: 837
Study: 26322232

Group type: EXPERIMENTAL
Intervention: Stay active advice
Number of subjects: 99

Group type: COMPARATOR
Intervention: Adjust activity advice
Number of subjects: 99
Study: 22968852

Group type: COMPARATOR
Intervention: Cilostazol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sarpogrelate
Number of subjects: 20
Study: 21789661

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 19137482

Group type: EXPERIMENTAL
Intervention: Psychotherapy interventions focusing on common factors and therapeutic alliance.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trials (RCT) of psychotherapies.
Number of subjects: 0
Study: 17460370

Group type: EXPERIMENTAL
Intervention: Benidipine added to ARB (Group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Benidipine administered first, then ARB increased (Group B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cost-effectiveness comparison
Number of subjects: 32
Study: 15502020

Group type: EXPERIMENTAL
Intervention: S(+)-ketamine (75 microg/kg bolus followed by continuous infusion of 1.25 microg . kg(‐1) . min(‐1) for 48 h)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (normal saline bolus and infusion)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: S(+)-ketamine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 11913480

Group type: EXPERIMENTAL
Intervention: Dofetilide 500 microg twice daily
Number of subjects: 135

Group type: COMPARATOR
Intervention: Sotalol 160 mg twice daily
Number of subjects: 135
Study: 9141577

Group type: EXPERIMENTAL
Intervention: Umbilical Doppler examination between 28 and 34 weeks of gestation
Number of subjects: 4187

Group type: COMPARATOR
Intervention: No routine umbilical Doppler
Number of subjects: 4187
Study: 7955239

Group type: EXPERIMENTAL
Intervention: Right internal thoracic artery (RITA) grafts
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Left internal thoracic artery (LITA) grafts
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: RITA grafts to left anterior descending (LAD) coronary artery
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: LITA grafts to left anterior descending (LAD) coronary artery
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Internal thoracic arteries used to bypass vessels other than the LAD
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Free grafts using segments of the RITA
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Saphenous vein grafts
Number of subjects: 67